Clinical Ink Ranked Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™
Clinical Ink today announced it ranked on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.
Clinical Ink’s Chief Executive Officer, Ed Seguine, credits the 293% growth to expertise in highly complex therapeutic areas (Alzheimer's, Lupus, COVID) and novel execution models such as decentralized and remote trials. Seguine stated, “Clinical Ink has consistently delivered results for our customers and earned their trust. We’ve always been at the forefront of innovation with technologies that simplify and accelerate complex clinical trial activities. The recent acquisition of Digital Artefacts will drive future growth as we lead the next wave of innovation by simplifying the adoption of digital endpoints.”
About the 2021 Deloitte Technology Fast 500™
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
Clinical Ink ranked No. 393 on the Deloitte Technology Fast 500™.
About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis™ eSource clinical technology and configurable direct data capture, eCOA, patient engagement, telehealth, eConsent, and instrumented data collection modules provide a suite of solutions for capturing and integrating electronic data from sites, clinicians, caregivers, and patients at its source. Clinical Ink’s therapeutic-area-specific approach to study design and data capture – with specific expertise in neurocognitive testing – enables more precise scales for cognitive and human factors assessments, including performance, behavior, movement, and all real-world activity.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006158/en/
Contact information
Chris Crucitti
Chief Commercial Officer
Clinical Ink
Phone: +1 917-743-0158
Email: chris.crucitti@clinicalink.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Unveils Advanced Matter over Thread Modules for Seamless Device Interoperability13.11.2025 11:00:00 EET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announced the launch of the KGM133S, the first in a range of Matter over Thread modules that provides innovative solutions for applications such as smart door locks, sensors, and lighting, helping the smart home industry overcome connectivity barriers and advance toward a new era of more efficient and seamless development. The KGM133S series modules are built based on the Silicon Labs EFR32MG24 chip, supporting the latest Matter 1.4 protocol. The modules are designed to enable seamless linkage of home devices across ecosystems, including Apple Home, Google Home, Amazon Alexa and Samsung SmartThings. “Protocol fragmentation remains one of the biggest obstacles to seamless smart device connectivity, and the Matter protocol is the key to overcoming it,” said Delbert Sun, Deputy General Manager at Quectel Wireless Solutions. “With our new Matter over Thread modules, we are helping the industry achieve true inter
SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 10:57:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).
IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 10:56:00 EET | Press release
IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research, a leap towards the next generation of quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113614564/en/ The first release of IQM Halocene will be a 150-qubit quantum computer with advanced error correction functionality. The system will enable users to advance their error correction capabilities, error correction research and to create intellectual property with logical qubits. In addition, the Halocene product line will allow execution of Noisy Intermediate Scale (NISQ) algorithms and the development of error mitigation techniques. “Halocene is the result of co-developing our technology stack with our partners and customers as we build
JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 10:45:00 EET | Press release
JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discovery for oncology. Crown Bioscience's Global Biospecimens business, headquartered in Hamburg, Germany
Ohmium Breaks Barriers: Exceeds 2030 Industry Targets of 10 GW/ton to Achieve 18 GW/ton Iridium Utilization13.11.2025 10:05:00 EET | Press release
Ohmium International Inc., a leading provider of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has surpassed the PEM electrolyzer industry's 2030 target of 10 GW per ton to attain an 18 GW per ton iridium utilization rate. Ohmium has made significant technological advancements which have resulted in reducing its iridium usage by 50% in its Lotus electrolyzer, Mark 2. This enhances the cost-competitiveness of green hydrogen production by reducing the overall cost of its PEM electrolyzers, which have been impacted by the cost of the precious metal, iridium. Dr. Chock Karuppaiah, Ohmium Chief Science and Technology Officer, said, "We've made significant strides in reducing iridium usage in our PEM electrolyzers, exceeding the 2030 industry target of 10 GW per ton. We've achieved a utilization rate of 18 GW per ton. This innovation is crucial, as iridium is one of the most expensive materials in electrolyzer manufacturing.” Dr. Markus Tacke, Ohmiu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom